Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B

BACKGROUND: Tenofovir amibufenamide (TMF) can provide more efficient delivery than tenofovir disoproxil fumarate (TDF). AIM: To compare the efficacy and safety of TMF and TDF for 48 weeks in patients with chronic hepatitis B (CHB). METHODS: We performed a randomised, double‐blind, non‐inferiority st...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhihong, Jin, Qinglong, Zhang, Yuexin, Gong, Guozhong, Wu, Guicheng, Yao, Lvfeng, Wen, Xiaofeng, Gao, Zhiliang, Huang, Yan, Yang, Daokun, Chen, Enqiang, Mao, Qing, Lin, Shide, Shang, Jia, Gong, Huanyu, Zhong, Lihua, Yin, Huafa, Wang, Fengmei, Hu, Peng, Xiao, Ling, Li, Chuan, Wu, Qiong, Sun, Chang’an, Niu, Junqi, Hou, Jinlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Randomised Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292801/
https://www.ncbi.nlm.nih.gov/pubmed/34587302
http://dx.doi.org/10.1111/apt.16611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292801/
https://www.ncbi.nlm.nih.gov/pubmed/34587302
http://dx.doi.org/10.1111/apt.16611

Ejemplares similares